State Street’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

State Street’s Portfolio RVPH Stock Details RVPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,160	Closed	-$14K	–	4255
2026 Q1	$14K	Hold	19,160	–	–	﹤0.01%	4237
2025 Q4	$107K	Buy	19,160 +12,825	+202%	+$143K	﹤0.01%	4037
2025 Q3	$46.7K	Hold	6,335	–	–	﹤0.01%	4163
2025 Q2	$48.3K	Hold	6,335	–	–	﹤0.01%	4106
2025 Q1	$121K	Buy	6,335 +1,365	+27%	+$42.9K	﹤0.01%	3930
2024 Q4	$180K	Buy	4,970 +1,400	+39%	+$39K	﹤0.01%	3876
2024 Q3	$103K	Hold	3,570	–	–	﹤0.01%	3973
2024 Q2	$91.4K	Buy	3,570 +410	+13%	+$18.6K	﹤0.01%	4032
2024 Q1	$239K	Sell	3,160 -115	-4%	-$9.11K	﹤0.01%	3832
2023 Q4	$337K	Buy	3,275 +1,055	+48%	+$94.7K	﹤0.01%	3745
2023 Q3	$217K	Hold	2,220	–	–	﹤0.01%	3918
2023 Q2	$260K	Hold	2,220	–	–	﹤0.01%	3922
2023 Q1	$186K	Hold	2,220	–	–	﹤0.01%	4102
2022 Q4	$189K	Buy	+2,220	New	+$169K	﹤0.01%	4125

Other funds holding RVPH

ECM

EMC Capital Management Houston, Texas $253M AUM

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

PUI

Purpose Unlimited Inc Toronto $2.62B AUM

MGI

Miller Global Investments Dallas, Texas $121M AUM

MWM

Mosley Wealth Management Anaheim, California $314M AUM

State Street's RVPH Position: Q2 2026 in Review

State Street sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2026, closing a stake of 19,160 shares — an estimated $14K sold.

State Street first reported a position in RVPH in Q4 2022 and held it in 14 quarters. The position peaked at $337K in Q4 2023. 5 funds tracked by Wall St. Rank hold RVPH as of Q2 2026.

State Street reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2026 after selling out during the quarter.
State Street sold 19,160 REVIVA PHARMA HLDGS INC shares in Q2 2026, an estimated $14K.
State Street first reported a position in REVIVA PHARMA HLDGS INC in Q4 2022 and held it in 14 quarters.
State Street's REVIVA PHARMA HLDGS INC position peaked at $337K in Q4 2023.
5 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.